Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFIRM-AL Japan
jRCT2031220037Phase 3Suspended
- Sponsor
- Prothena Corporation
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in light-chain amyloidosis comparing Birtamimab plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Time to all-cause mortality. Started Jan 2023; status: suspended.
02
Drugs
birtamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on jRCT2031220037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220037.